We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Test Differentiates Malignant Prostate Cancer Grades

By LabMedica International staff writers
Posted on 25 May 2016
A promising new test has been introduced that detects prostate cancer more precisely than current tests, by identifying molecular changes in the prostate specific antigen (PSA) protein and can also differentiate between high-risk and low-risk disease, as well as benign conditions.

Although widely used, the current PSA test relies on detection strategies that have poor specificity for cancer, 25% of men who have a prostate biopsy due to an elevated PSA level actually have prostate cancer, and an inability to determine the aggressiveness of the disease.

Urologists at the Cleveland Clinic (OH, USA) carried out a clinical trial, which involved six healthcare institutions and 132 patients, to date. More...
It examined the ability of novel test to distinguish patients with and without biopsy-confirmed evidence of cancer. It also evaluated the test's precision in differentiating patients with high-grade (Gleason =7) cancer from those with low-grade (Gleason = 6) disease and benign findings after standard ultrasound-guided biopsy of the prostate. The scientists obtained 99 plasma samples from multiple clinical sites, collected within 30 days prior to prostate biopsy from patients with blood PSA between 2 and 26 ng/mL. The new test was evaluated against 12 core transrectal ultrasonography guided biopsy results as gold standard.

The new test is called the IsoPSA test (Cleveland Diagnostics, Inc, Cleveland, OH, USA) identifies the molecular structural changes in protein biomarkers. It is able to detect cancer by identifying these structural changes, as opposed to current tests that simply measure the protein's concentration in a patient's blood. Substituting the IsoPSA structure-based composite index for the standard PSA resulted in improvement in diagnostic accuracy. Compared with serum PSA testing, IsoPSA performed better in both sensitivity and specificity.

Eric Klein, MD, chair of Cleveland Clinic's Glickman Urological & Kidney Institute, said, “While the PSA test has undoubtedly been one of the most successful biomarkers in history, its limitations are well known. Even currently available prostate cancer diagnostic tests rely on biomarkers that can be affected by physiological factors unrelated to cancer. These study results show that using structural changes in PSA protein to detect cancer is more effective and can help prevent unneeded biopsies in low-risk patients.” The study was presented at the American Urological Association annual meeting held May 6-10, 2016, in San Diego, CA, USA.

Related Links:
Cleveland Clinic
Cleveland Diagnostics


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining System
RAL DIFF-QUIK
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.